Corbus Pharmaceuticals Holdings, Inc. (CRBP) revealed on Wednesday that Dominic Smethurst has been appointed as its new Chief Medical Officer (CMO). Smethurst brings with him more than two decades of experience from the pharmaceutical and biotechnology industry, including a significant contribution to the UK's National Health Service. Prior to this, he served as the CMO of Bicycle Therapeutics. In the pre-market activity, the shares of Corbus increased by 2.61% on the Nasdaq, trading at $26.75.